Marianna Fontana

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6813898/publications.pdf

Version: 2024-02-01

124 papers	13,984 citations	23567 58 h-index	22166 113 g-index

124 all docs	124 docs citations	124 times ranked	9311 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, 2021, 385, 493-502.	27.0	807
3	Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2013, 6, 488-497.	5.3	517
4	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579.	1.6	442
5	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
6	Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping. Circulation: Cardiovascular Imaging, 2013, 6, 392-398.	2.6	399
7	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	2.2	396
8	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
9	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
10	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2.2	310
11	Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine, 2015, 373, 1106-1114.	27.0	304
12	Magnetic Resonance in TransthyretinÂCardiac Amyloidosis. Journal of the American College of Cardiology, 2017, 70, 466-477.	2.8	290
13	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26.	1.6	288
14	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423.	12.6	286
15	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature, 2022, 601, 110-117.	27.8	280
16	Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal, 2021, 42, 1866-1878.	2.2	274
17	Reverse Myocardial Remodeling FollowingÂValve Replacement in PatientsÂWith Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 860-871.	2.8	266
18	Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis. Circulation: Cardiovascular Imaging, 2013, 6, 34-39.	2.6	261

#	Article	IF	Citations
19	T1 Mapping for Myocardial Extracellular Volume Measurement by CMR. JACC: Cardiovascular Imaging, 2013, 6, 955-962.	5.3	245
20	Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science, 2022, 377, .	12.6	241
21	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230
22	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	210
23	Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 87.	3.3	207
24	Prevalence and Outcomes of Concomitant Aortic Stenosis and CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2021, 77, 128-139.	2.8	187
25	Native T1 and Extracellular Volume inÂTransthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 810-819.	5.3	172
26	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology, 2020, 5, .	11.9	172
27	Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 99.	3.3	154
28	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
29	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	7.3	146
30	Myocardial Edema and Prognosis inÂAmyloidosis. Journal of the American College of Cardiology, 2018, 71, 2919-2931.	2.8	145
31	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European Heart Journal, 2017, 38, 1905-1908.	2.2	144
32	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMRÂtoÂDetect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. JACC: Cardiovascular Imaging, 2019, 12, 1958-1969.	5.3	140
33	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
34	Cardiac amyloidosis. Clinical Medicine, 2018, 18, s30-s35.	1.9	135
35	Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathologyÂin patients referred for transcatheter aortic valve implantation. European Heart Journal, 2020, 41, 2759-2767.	2.2	128
36	Automatic Measurement of the MyocardialÂInterstitium. JACC: Cardiovascular Imaging, 2016, 9, 54-63.	5.3	127

#	Article	IF	Citations
37	COVID-19. Circulation, 2020, 142, 1120-1122.	1.6	126
38	Noncontrast Magnetic Resonance for theÂDiagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 69-80.	5.3	125
39	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal Cardiovascular Imaging, 2017, 18, 1344-1350.	1.2	124
40	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	2.2	121
41	Cardiovascular magnetic resonance for amyloidosis. Heart Failure Reviews, 2015, 20, 133-144.	3.9	120
42	Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833.	5.3	113
43	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC: Cardiovascular Imaging, 2021, 14, 189-199.	5.3	113
44	Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2018, 71, 463-464.	2.8	111
45	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	2.2	108
46	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
47	The Prognostic Significance of Quantitative Myocardial Perfusion: An Artificial Intelligence Based Approach Using Perfusion Mapping. Circulation, 2020, 141, 1282-1291.	1.6	100
48	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
49	Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine, 2018, 10, .	12.4	94
50	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2022, 375, 183-192.	12.6	91
51	CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC: Cardiovascular Imaging, 2018, 11, 152-154.	5.3	90
52	Sex Dimorphism in the MyocardialÂResponse to Aortic Stenosis. JACC: Cardiovascular Imaging, 2018, 11, 962-973.	5.3	85
53	Diagnostic imaging of cardiac amyloidosis. Nature Reviews Cardiology, 2020, 17, 413-426.	13.7	84
54	Myocardial Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 2345-2356.	5.3	74

#	Article	IF	Citations
55	T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 73.	3.3	70
56	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
57	Clinical Importance of Left Atrial Infiltration in Cardiac TransthyretinÂAmyloidosis. JACC: Cardiovascular Imaging, 2022, 15, 17-29.	5.3	67
58	High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 73, 1733-1734.	2.8	65
59	Dark blood late enhancement imaging. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 77.	3.3	64
60	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	13.7	64
61	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARSâ€'CoV-2 infection. EBioMedicine, 2021, 65, 103259.	6.1	61
62	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe, The, 2021, 2, e508-e517.	7.3	52
63	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
64	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. European Heart Journal, 2022, 43, 333-341.	2.2	45
65	Quantitation of ^{99m}Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 203-210.	3.0	42
66	Cardiac Amyloidosis: Updates in Imaging. Current Cardiology Reports, 2019, 21, 108.	2.9	41
67	T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure. Current Cardiovascular Imaging Reports, 2014, 7, 9287.	0.6	37
68	Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 91.	3.3	36
69	Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease. Circulation: Cardiovascular Imaging, 2020, 13, e010171.	2.6	35
70	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
71	Automated Inline Analysis of Myocardial Perfusion MRI with Deep Learning. Radiology: Artificial Intelligence, 2020, 2, e200009.	5.8	32
72	Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology, 2018, 271, 152-160.	1.7	31

#	Article	IF	Citations
73	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. JACC: Cardiovascular Imaging, 2020, 13, 2546-2557.	5.3	30
74	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Scientific Reports, 2019, 9, 1388.	3.3	27
75	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27
76	Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2020, 13, e009901.	2.6	26
77	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 1304-1311.	1.2	26
78	A simple echocardiographic score to rule out cardiac amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13449.	3.4	24
79	Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment. Circulation: Cardiovascular Imaging, 2021, 14, e009025.	2.6	24
80	Relative Left Ventricular Apical Sparing of Longitudinal Strain in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 1174-1176.	5.3	23
81	Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396.	7.1	23
82	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949.	3.1	22
83	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. Journal of the American Heart Association, 2019, 8, e012097.	3.7	21
84	Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Research, 2020, 5, 179.	1.8	21
85	Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. Circulation: Cardiovascular Imaging, 2021, 14, CIRCIMAGING121012506.	2.6	19
86	Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype. Diagnostics, 2020, 10, 770.	2.6	19
87	HLAâ€DR polymorphism in SARSâ€CoVâ€2 infection and susceptibility to symptomatic COVIDâ€19. Immunology, 2022, 166, 68-77.	4.4	18
88	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
89	Cardiac Amyloidosis: A Review of Current Imaging Techniques. Frontiers in Cardiovascular Medicine, 2021, 8, 751293.	2.4	16
90	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. European Heart Journal Cardiovascular Imaging, 2021, 22, 273-281.	1.2	15

#	Article	IF	Citations
91	Ongoing Exercise Intolerance Following COVIDâ€19: A Magnetic Resonanceâ€“Augmented Cardiopulmonary Exercise Test Study. Journal of the American Heart Association, 2022, 11, e024207.	3.7	15
92	Imaging-Guided Treatment for Cardiac Amyloidosis. Current Cardiology Reports, 2022, 24, 839-850.	2.9	13
93	001â€…Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. Heart, 2017, 103, A1-A2.	2.9	12
94	AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology. Journal of Cardiovascular Magnetic Resonance, 2014, 16, P341.	3.3	11
95	Staging Cardiac Amyloidosis With CMR. JACC: Cardiovascular Imaging, 2016, 9, 1278-1279.	5.3	10
96	Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Research, 2020, 5, 179.	1.8	10
97	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science, 2021, , eabm0811.	12.6	10
98	Quantitative Myocardial Perfusion Predicts Outcomes in Patients With Prior SurgicalÂRevascularization. Journal of the American College of Cardiology, 2022, 79, 1141-1151.	2.8	10
99	A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. BMC Medical Imaging, 2017, 17, 3.	2.7	9
100	Myocardial Perfusion Imaging After Severe COVID-19 Infection Demonstrates Regional Ischemia Rather Than Global Blood Flow Reduction. Frontiers in Cardiovascular Medicine, 2021, 8, 764599.	2.4	9
101	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478.	2.9	8
102	Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis. Heart, 2022, 108, 67-72.	2.9	8
103	The role of serial ^{99m}Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 38-49.	3.0	8
104	Extracellular volume with bolusâ€only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. Journal of Magnetic Resonance Imaging, 2018, 47, 1677-1684.	3.4	7
105	Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. Cardiology Clinics, 2021, 39, 389-402.	2.2	7
106	Bright-blood and dark-blood phase sensitive inversion recovery late gadolinium enhancement and T1 and T2 maps in a single free-breathing scan: an all-in-one approach. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 126.	3.3	7
107	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. European Heart Journal Cardiovascular Imaging, 2023, 24, 463-471.	1.2	7
108	Cardiovascular Magnetic Resonance Parametric Mapping Techniques: Clinical Applications and Limitations. Current Cardiology Reports, 2021, 23, 185.	2.9	5

#	Article	IF	Citations
109	Prognosis in Cardiac Amyloidosis by LGE. JACC: Cardiovascular Imaging, 2016, 9, 687-689.	5.3	4
110	028â€...Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping. Heart, 2017, 103, A24-A24.	2.9	3
111	The UK National Amyloidosis Centre. European Heart Journal, 2019, 40, 1661-1664.	2.2	3
112	A case report of eosinophilic granulomatosis and polyangiitis myocarditis presenting as ST elevation myocardial infarction and showing positive response to immunotherapy. European Heart Journal - Case Reports, 2019, 3, 1-6.	0.6	3
113	Analysis of Cardiac Amyloidosis Progression Using Model-Based Markers. Frontiers in Physiology, 2020, 11, 324.	2.8	3
114	Atrial Involvement in Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 732-734.	4.0	3
115	Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, O4.	3.3	2
116	Reply. Journal of the American College of Cardiology, 2018, 72, 1881.	2.8	2
117	A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis. Expert Opinion on Orphan Drugs, 2021, 9, 87-94.	0.8	2
118	The evolution of cardiovascular COVID-19 research. European Heart Journal, 2021, 42, 2953-2954.	2.2	2
119	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1294-1295.	5.3	1
120	Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 269-270.	3.0	1
121	Detailed Understating of CardiacÂAmyloidosis by CMR. JACC: Cardiovascular Imaging, 2020, 13, 1311-1313.	5.3	1
122	The Authorsâ€™ Reply. JACC: Cardiovascular Imaging, 2021, 14, 2268-2269.	5.3	1
123	The Authors Reply:. JACC: Cardiovascular Imaging, 2021, 14, 882-883.	5.3	0
124	Comparison of 99mTc-DPD Scintigraphy, CMR Imaging, and Echocardiography in Patients With V30M-Associated Hereditary Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2022, , .	5.3	0